JPRN-jRCT2080221426未知2 期
A phase 2 trial of FOLFIRINOX (L-OHP+CPT-11+5-FU/l-LV) in patients with previously untreated metastatic pancreatic cancer
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Histologically or cytologically proven pancreatic adenocarcinoma or adenosquamous carcinoma
- •-ECOG performance status (PS) :0-1
- •-Metastatic disease with measurable lesion based on RECIST criteria
排除标准
- •-Prior treatment with chemotherapy or radiotherapy
- •-Synchronous or metachronous cancer
- •-Serious concomitant disease
研究者
相似试验
进行中（未招募）
1 期
_RAS and B-RAF wild-type metastatic colorectal cancer.MedDRA version: 19.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2016-001490-33-FRICANCER209
已完成
2 期
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407, LAPC-mFOLFIRINOX/GnP-rP2)locally advanced pancreatic cancerJPRN-UMIN000023143Japan Clinical Oncology Group (JCOG)124
已完成
2 期
Phase II trial of modified FOLFIRINOX (irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin) in patients with untreated metastatic pancreatic canceruntreated metastatic pancreatic cancerJPRN-UMIN000013301Cancer Institute Hospital65
招募中
2 期
eoadjuvant FOLFIRINOXPancreatic cancer, Neoadjuvant therapyPancreatic cancerJPRN-jRCT1041220027Yamashita Tatsuya50
招募中
不适用
Phase II study of FOLFIRINOX for unresectable pancreatic cancer patients after discontinuation of Pegfilgrastimnresectable pancreatic cancerJPRN-UMIN000028055Kanazawa University Hospital33